GLP Watchdog

Oral GLP-1s: 10 Questions About Rybelsus, the Wegovy Pill and Foundayo

Last verified November 2026 · 10 questions · 11 PubMed citations

Questions taken from r/Semaglutide, r/Ozempic, r/Zepbound

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

An oral GLP-1 is not simply an injection in tablet form, and the differences decide whether it works for you. Two of these drugs are peptides smuggled past the stomach by an absorption enhancer, which is why the fasting instructions are non-negotiable rather than fussy; the third is a small molecule built to be swallowed. Where a dose is quoted, we use the number that will be on your prescription, because trial reports and labels sometimes count the same dose differently. Foundayo is the clearest case and is explained in its own answer. Each answer links to the papers and labels it rests on.

Questions and answers

Q1.Why the empty stomach and the 30-minute wait?

Because without it, most of the dose never reaches you. Semaglutide is a peptide and your stomach digests peptides, so each tablet carries an absorption enhancer called SNAC that raises the pH in a small pocket around the pill and helps the intact molecule cross the stomach lining. That trick only works if the tablet is pressed against the stomach wall with almost no fluid and nothing else on top of it, which is the whole reason for the rule. The label is specific: first thing on waking, with plain water (4 ounces at most), and then a clear half hour before anything else goes down (food, other drinks, other tablets). Pharmacokinetic studies show food or extra water cuts exposure substantially. Shortening that gap, or chasing the pill with coffee, is probably the commonest reason real-world results trail the trials.

Source thread ↗PMID 30429357 ↗PMID 30565096 ↗

Q2.Does the pill work as well as the shot?

It depends entirely on which pill. At the diabetes doses (7 mg and 14 mg), oral semaglutide delivers clearly less weight loss than the weekly injection: PIONEER 4 recorded about 4.4 kg at 26 weeks on 14 mg, which beat liraglutide and placebo but is not in the same territory as the shot. At a much higher daily dose the gap narrows sharply. OASIS 1 ran 68 weeks in adults who had obesity but not diabetes, and reported roughly 15.1% mean loss on 50 mg of the tablet against 2.4% on placebo; PIONEER PLUS found the same dose-dependence among people with diabetes. So compare by dose, not by format. The low-dose tablet trails the injection substantially. The 25 mg Wegovy tablet sits below OASIS 1's 50 mg dose but still closes most of the distance, with 13.6% mean loss at 64 weeks against 2.2% on placebo in the trial behind its approval.

Source thread ↗PMID 31186120 ↗PMID 31186300 ↗PMID 37385278 ↗PMID 37385279 ↗PMID 40934115 ↗

Q3.Is the Wegovy pill just Rybelsus under another name?

No, and assuming so is an expensive mistake in both directions. They are both oral semaglutide using the same SNAC absorption route, from the same manufacturer, but they are approved for different things at very different strengths. Rybelsus is a diabetes drug at 3, 7 or 14 mg daily. The Wegovy tablet is 25 mg daily for chronic weight management. In the 64-week trial behind its approval it produced 13.6% mean loss against 2.2% on placebo, and OASIS 1, which tested a higher 50 mg daily dose, reported roughly 15.1% at 68 weeks. That strength difference is why average results run near 14-15% on the weight-strength tablets and nearer 4-6% on Rybelsus 14 mg. Two 14 mg Rybelsus tablets are also not equivalent to one 25 mg Wegovy tablet. Absorption depends on the ratio of SNAC to semaglutide within a single tablet, so doubling up changes the formulation rather than the dose. Both still need the empty stomach and the 30-minute wait.

Source thread ↗PMID 30429357 ↗PMID 37385278 ↗PMID 40934115 ↗

Q4.What is Foundayo, and can I get it yet?

Foundayo is orforglipron, and it differs from every GLP-1 before it in one structural way: it is a small molecule, not a peptide. That removes the fasting rule entirely, because there is no fragile peptide to smuggle past your stomach acid and no absorption enhancer to protect. The label lets you take it whenever you like, fed or fasted. The instructions that do hold are to swallow the tablet whole (never break, crush or chew it) and never take more than one a day. It was approved in April 2026 for long-term weight management, either in adults with obesity or in those carrying excess weight alongside a related condition. It has no diabetes indication. Approval rested on a 72-week phase 3 trial in 3,127 adults without diabetes, plus a diabetes trial. Supply is staged through 2026, so expect patchy pharmacy stock rather than an even rollout.

Source thread ↗PMID 40960239 ↗PMID 40544435 ↗PMID 37351564 ↗

Q5.What is the real Foundayo dose ladder?

Six steps, each held for 30 days or longer. It starts at 0.8 mg, climbs to 2.5 mg and 5.5 mg, and from there upward through 9 mg and 14.5 mg to a ceiling of 17.2 mg, depending on response and tolerability. That is what your prescription will say. The published trial uses different numbers, which can make ours look wrong. It was run with an investigational formulation dosed at 6, 12 and 36 mg, and its top arm produced about 11.2% mean weight loss at 72 weeks against 2.1% on placebo. The FDA label restates those same arms as their Foundayo equivalents: 5.5 mg, 9 mg and 17.2 mg. So 36 mg in the journal and 17.2 mg on your bottle are the same treatment, and anyone quoting 36 mg as a dose you might be prescribed has misread it. Holding a step an extra month is normal if a step is rough.

Source thread ↗PMID 40960239 ↗PMID 37351564 ↗

Q6.Nothing is happening on 3 mg Rybelsus. Is it not working?

It is working as designed, because 3 mg is not a treatment dose. The label treats it as a 30-day tolerability lead-in before stepping to 7 mg, and then to 14 mg a month later if targets are unmet. The trial data are blunt about this: PIONEER 1 found 3 mg produced essentially no weight loss beyond placebo, while the two higher strengths each did more than the one below them, for both weight and HbA1c. In PIONEER 4, everyone in the tablet arm was stepped up to 14 mg, and that is the dose behind its 4.4 kg. So flat results in week three on 3 mg are the expected pattern. Some people even gain slightly in that first month, often because early queasiness pushes them toward frequent, calorie-dense snacking. The answer is to finish the lead-in and step up with your prescriber, not to conclude the drug does nothing.

Source thread ↗PMID 31186300 ↗PMID 31186120 ↗

Q7.Can I crush or split the tablet?

No, and unlike most 'swallow whole' instructions, this one changes how much drug you get. The tablet is built so the SNAC enhancer releases in a concentrated pocket right against the stomach lining as it dissolves. Crushing, splitting or chewing scatters that pocket, and the mechanism depends on it being concentrated in one small area. The same fragility shows up elsewhere: even taking the tablet with extra water or with food cuts semaglutide exposure sharply. A broken tablet is best thought of as a different and much weaker drug rather than the same dose in pieces. If swallowing a small pill is the problem, that is a real reason to ask about an injectable, which has no absorption ritual at all. Foundayo also must be swallowed whole, though for formulation reasons rather than SNAC ones.

Source thread ↗PMID 30429357 ↗PMID 30565096 ↗

Q8.Can I move from Rybelsus to the weekly injection?

Yes, and it is one of the easier switches in this class, because it is the same molecule either way. The injection simply bypasses the absorption problem the tablet spends so much effort solving, giving steadier and higher blood levels across the week. Common practice is to move from 14 mg daily to 0.5-1 mg weekly as a starting point and titrate from there, though dose equivalence between the two is approximate rather than calculated. Work it out with your prescriber; there is no conversion table to apply. No trial cited here compared the tablet with injected semaglutide head to head (PIONEER 4 set Rybelsus 14 mg against injected liraglutide), but the injection's higher, steadier blood levels point toward more effect, not less. For weight specifically, the 2.4 mg injection reaches around 15-17% in trials.

Source thread ↗PMID 31186120 ↗PMID 37385278 ↗

Q9.Is the tablet safe for my heart?

It has its own cardiovascular outcomes trial, which is more than most weight drugs can say. PIONEER 6 enrolled roughly 3,183 people who had type 2 diabetes together with a high risk of cardiac events, comparing the 14 mg tablet against placebo across a median of about 16 months. Major adverse cardiac events occurred in 3.8% on the drug against 4.8% on placebo. The trial was designed to rule out harm, not to prove benefit, so the numerically better result cannot be claimed as a reduction the way SUSTAIN-6's 26% cut can for the injection. Taken together, the two trials support the position that this molecule does not add cardiovascular risk for people with type 2 diabetes, and may take some away. Nobody whose family or personal history includes medullary thyroid cancer, or who has MEN 2, should take any semaglutide product; that is a boxed contraindication.

Source thread ↗PMID 31185157 ↗

Q10.Does Foundayo upset your stomach like the injections?

Yes, and in the same shape: nausea, diarrhea, constipation and vomiting are its most common adverse events, they cluster during titration, and they settle once a dose is held. In the 72-week phase 3 trial, adverse events led 5.3-10.3% of participants on the drug to stop, against 2.7% on placebo. The large majority completed, but the discontinuation rate is real and rises with dose. The six-step monthly ladder exists to blunt this, and holding a step an extra month is a normal request. Foundayo has one real advantage over the peptide tablets. With no fasting rule you can take it alongside a small meal, and eating something with a dose is among the cheapest ways to blunt nausea, an option unavailable to anyone on Rybelsus. Most of it is mild to moderate, and most of it passes.

Source thread ↗PMID 40960239 ↗PMID 37351564 ↗PMID 40544435 ↗

References

  1. 1.Aroda VR, Rosenstock J, Terauchi Y, et al PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Diabetes Care. 2019. PMID: 31186300.
  2. 2.Pratley R, Amod A, Hoff ST, et al Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Lancet. 2019. PMID: 31186120.
  3. 3.Husain M, Birkenfeld AL, Donsmark M, et al Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med. 2019. PMID: 31185157.
  4. 4.Knop FK, Aroda VR, do Vale RD, et al Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 2023. PMID: 37385278.
  5. 5.Wharton S, Lingvay I, Bogdanski P, et al Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity N Engl J Med. 2025. PMID: 40934115.
  6. 6.Aroda VR, Aberle J, Bardtrum L, et al Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial Lancet. 2023. PMID: 37385279.
  7. 7.Wharton S, Aronne LJ, Stefanski A, et al Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment N Engl J Med. 2025. PMID: 40960239.
  8. 8.Rosenstock J, Hsia S, Nevarez Ruiz L, et al Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes N Engl J Med. 2025. PMID: 40544435.
  9. 9.Wharton S, Blevins T, Connery L, et al Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity N Engl J Med. 2023. PMID: 37351564.
  10. 10.Granhall C, Donsmark M, Blicher TM, et al Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes Clin Pharmacokinet. 2019. PMID: 30565096.
  11. 11.Buckley ST, Baekdal TA, Vegge A, et al Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist Sci Transl Med. 2018. PMID: 30429357.

Questions are paraphrased from public forum threads and linked to their source where one was recorded. Answers summarize published trial data and FDA labeling. This is not medical advice, and no part of it replaces the judgment of whoever prescribes for you.